上次评级 买入 [Table_A [Table_Author] 武浩 电力设备与新能源行业首席分 uthor] 析师 执业编号：S1500520090001 联系电话：010-83326711 邮 箱：wuhao@cindasc.com 孙然 电力设备与新能源行业分析师 执业编号：S1500524080003 联系电话：18721956681 邮 箱：sunran@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127 号金 隅大厦B座 邮编：100031 证券研究报告 公司研究 [Table_ReportType] 点评报告 [Table_StockAndRank] 盛弘股份 (300693.SZ) 投资评级 买入 [Table_Title] 充电桩业务高增，AIDC 打开增长空间 [Table_ReportDate] 2025 年 4 月 9 日 [Table_S 事件：公司ummar2024 y] 年实现营业收入 30.36 亿元，同比+14.53%；归母净利润 4.29 亿元，同比+6.49%；实现扣非归母净利润 4.17 亿元 ...

公司研究 [Table_ReportType] 公司点评报告 [晨Ta光bl生e_物Sto(c3k0A0n1d3Ra8n)k] 、 全年收入平稳，核心产品销量增加。分品类看，公司植提类业务收入 31.29 亿元，同比增长 8.25%；棉籽类业务收入 34.75 亿元，同比下降 2.07%。分地区看，公司国内收入 59.41 亿元，同比+6.24%；国外收 入 10.53 亿元，同比-17.68%。核心产品中，辣椒红年内销量逐季回升， 全年实现销量 9000 吨以上；辣椒精售价随原料成本下调，均价同比下 降 25%，销量同比+56%，带动收入增长 17%；叶黄素销量恢复增长， 全年销量超 4.80 亿克；甜菊糖收入 2.31 亿元，同比+54%，创历史新 高。 毛利率受行业周期影响下降，棉籽计提影响利润。受行业周期和竞争影 响，公司主要产品价格下降，24 年毛利率为 7.96%，同比-3.65pct，其 中植提类业务毛利率15.39%，同比-4.54pct；棉籽类业务毛利率0.18%， 同比-3.48pct。费用端整体略有增加，销售费用率、管理费用率、研发 费 用 率 和 财 务 费 用 率 同 比 分 别 - ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The report highlights a dual network layout of "Guangdong and Guangxi distribution + national retail," emphasizing the acceleration of performance growth through "quality improvement and efficiency enhancement" [2] - The company reported a revenue of 74.378 billion yuan in 2024, a decrease of 1.46% year-on-year, and a net profit attributable to shareholders of 642 million yuan, down 59.83% year-on-year [2] - The report anticipates a revenue recovery in 2025, projecting revenues of 75.655 billion yuan, with a net profit of 1.333 billion yuan, reflecting a year-on-year growth of approximately 107.5% [6] Summary by Sections Financial Performance - In 2024, the distribution segment achieved a revenue of 52.984 billion yuan, growing by 1.98% year-on-year, while net profit decreased by 12.74% to 922 million yuan [3] - The retail segment, represented by "Guoda Pharmacy," reported a revenue of 22.357 billion yuan, down 8.41% year-on-year, with a net loss of 1.104 billion yuan, a decline of 309.53% [4] - The company recorded a significant asset impairment loss of 984 million yuan in Q4 2024, primarily related to goodwill and intangible assets [2] Strategic Initiatives - The company is focusing on enhancing its traditional business while expanding innovative operations, including the introduction of 117 new innovative drugs and a 19% increase in innovative drug distribution in the Guangxi region [3] - The strategic direction for Guoda Pharmacy has shifted from "scale growth" to "high-quality development," leading to the closure of over 1,270 stores [4] Future Outlook - The company expects to achieve revenues of 77.229 billion yuan and 79.439 billion yuan in 2026 and 2027, respectively, with net profits projected at 1.446 billion yuan and 1.567 billion yuan [6] - The report maintains a "Buy" rating, indicating confidence in the company's potential for performance reversal in 2025 [6]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The report highlights a dual network layout of "Guangdong and Guangxi distribution + national retail," emphasizing the acceleration of performance growth through "quality improvement and efficiency enhancement" [2] - The company reported a revenue of 74.378 billion yuan in 2024, a decrease of 1.46% year-on-year, and a net profit attributable to shareholders of 642 million yuan, down 59.83% year-on-year [2] - The report anticipates a revenue recovery in 2025, projecting revenues of 75.655 billion yuan, with a net profit of 1.333 billion yuan, reflecting a year-on-year growth of approximately 108% [6] Summary by Sections Revenue and Profitability - In 2024, the company's distribution segment achieved a revenue of 52.984 billion yuan, growing by 1.98% year-on-year, while net profit in this segment fell by 12.74% to 922 million yuan [3] - The retail segment, represented by "Guangda Pharmacy," reported a revenue of 22.357 billion yuan, a decline of 8.41%, with a net loss of 1.104 billion yuan, marking a 309.53% decrease [4] Strategic Initiatives - The company is focusing on high-quality development, shifting its strategy from "scale growth" to "high-quality development," and has closed over 1,270 underperforming stores [4] - The introduction of innovative products has been a priority, with the pharmacy segment achieving sales of 1.89 billion yuan from innovative business, including O2O and B2C sales [4] Financial Forecast - The financial forecast indicates a gradual recovery, with expected revenues of 77.229 billion yuan in 2026 and 79.439 billion yuan in 2027, alongside net profits of 1.446 billion yuan and 1.567 billion yuan respectively [5][6] - The report projects an increase in operating cash flow by approximately 11% in 2024, reaching 3.271 billion yuan, driven by improved management of working capital [6]

公用事业合理定价，水价上调持续推进 2025 年 4 月 8 日 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title公用事业合理定价，水价上调持续推进 ] 证券研究报告 行业研究 [行业Table专题_ReportType] 报告 | 左前明 能源行业首席分析师 | | --- | | 执业编号：S1500518070001 | | 联系电话：010-83326712 | | 邮 箱：zuoqianming@cindasc.com | 郭雪 环保联席首席分析师 执业编号：S1500525030002 邮 箱：guoxue @cindasc.com 化工行业： 吴柏莹 环保行业分析师 执业编号：S1500524100001 邮 箱：wuboying@cindasc.com [Table_ReportDate] 2025 年 4 月 8 日 本期内容提要: 请阅读最后一页免责声明及信息披露 http://www.cindasc.com 2 [Table_S [➢Table_Summary 继上海、南 ...

等待宽松兑现 债券研究 ——2025 年 4 月流动性展望 [T专题able_ReportType] 报告 [Table_ReportTime] 2025 年 4 月 8 日 [Table_A 李一爽 uthor 固定收益 ] 首席分析师 执业编号：S1500520050002 联系电话：+8618817583889 邮 箱：liyishuang@cindasc.com 请阅读最后一页免责声明及信息披露 http://www.cindasc.com1 证券研究报告 信达证券股份有限公司 CINDASECURITIESCO.,LTD 北京市西城区宣武门西大街甲 127 号金 隅大厦 B 座 邮编：100031 3等待宽松兑现——2025 年 4 月流动性展望 [Table_ReportDate] 2025 年 4 月 8 日 [➢Table_Summary] 2 月超储率环比上升 0.2pct 至 1.2%，高于我们此前的预期，这主要是由于 央行对其他存款性公司债权上升 4337 亿，明显高于央行高频操作净回笼的 6706 亿以及其他存款性公司负债下降的 8075 亿元，相当于央行再度额外投 放 1.1 万亿， ...

Research and Development Center 行业研究 [Tabl 行业e_ReportType] 专题报告 [Table_StockAndRank] 轮胎行业 轮胎行业专题报告（2025 年 3 月）： 美国关税扰动市场，后续仍需关注变化 [Table_ReportTime] 2025 年 4 月 8 日 [Table_Industry] 证券研究报告 [Table_A 张燕生 uthor化工] 行业首席分析师 执业编号：S1500517050001 联系电话：+86 010-83326847 邮 箱：zhangyansheng@cindasc.com 洪英东 化工行业分析师 执业编号：S1500520080002 联系电话：+86 010-83326848 邮 箱： hongyingdong@cindasc.com 尹柳 化工行业分析师 执业编号：S1500524090001 联系电话：+86010-83326712 邮箱：yinliu@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅 大厦B座 邮编： ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report suggests a positive outlook on the company's growth potential and profitability [1]. Core Viewpoints - The company is expected to achieve a net profit attributable to shareholders of 29.15-38.47 million yuan in Q1 2025, representing a year-on-year growth of 150%-230%. The net profit after deducting non-recurring items is projected to be 14.34-20.08 million yuan, with a year-on-year growth of 400%-600% [1]. - The company is making substantial progress in its franchise business, with 30 new franchise stores opened by the end of March 2025, and a target of 500 new stores for the year [2]. - The company is enhancing its online presence through regular live streaming operations and plans to accelerate the development of quality content and supply chain [2]. - The company is actively pursuing AI digitalization, collaborating with partners to develop AI products and services, which are expected to contribute to future profitability [2]. - The company is positioned as a leader in the maternal and infant sector, with a strong store network and significant membership base, and is focusing on e-commerce and AI technology to build a comprehensive maternal and infant ecosystem [3]. Financial Summary - The company's total revenue is projected to grow from 8.753 billion yuan in 2023 to 15.701 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 14.8% [4]. - The net profit attributable to shareholders is expected to increase from 105 million yuan in 2023 to 625 million yuan in 2027, reflecting a significant growth trajectory [4]. - The company's gross margin is expected to remain stable, increasing slightly from 29.6% in 2023 to 29.9% in 2027 [4]. - The projected earnings per share (EPS) are expected to rise from 0.08 yuan in 2023 to 0.50 yuan in 2027, indicating strong earnings growth [4].

Investment Rating - The report assigns a "Buy" rating for the company, indicating that the stock price is expected to outperform the benchmark index by more than 15% [10]. Core Views - The company is expected to achieve a net profit attributable to shareholders of between 29.15 million to 38.47 million yuan in Q1 2025, representing a year-on-year growth of 150% to 230%. The non-recurring gains are estimated to be around 14.80 million to 18.40 million yuan, likely from government subsidies and investment income [1]. - The company is making substantial progress in its franchise business, with 30 new franchise stores opened by the end of March 2025, and a target of 500 new stores for the year [2]. - The company is enhancing its online presence through regular live streaming operations and has partnered with key influencers to support this initiative, aiming to create a new growth curve [2]. - The company is actively advancing its AI digitalization efforts, collaborating with partners to develop AI products and services, which are expected to become significant profit sources in the future [2]. - The company is positioned as a leader in the maternal and infant sector, with a strong store network and a large customer base, and is focusing on e-commerce and AI technology to build a comprehensive maternal and infant ecosystem [3]. Financial Summary - The company’s total revenue is projected to grow from 8.75 billion yuan in 2023 to 15.70 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 14.8% [4]. - The net profit attributable to shareholders is expected to increase significantly from 105 million yuan in 2023 to 625 million yuan in 2027, reflecting a CAGR of around 25% [4]. - The gross margin is expected to remain stable, increasing slightly from 29.6% in 2023 to 29.9% in 2027 [4]. - The report forecasts earnings per share (EPS) to rise from 0.08 yuan in 2023 to 0.50 yuan in 2027, with corresponding price-to-earnings (P/E) ratios decreasing from 121.15 to 20.37 over the same period [4].

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report indicates a positive outlook based on performance metrics and growth potential. Core Insights - The company reported Q1 2025 revenue of 3.161 billion yuan, a year-on-year increase of 17.93%, and a net profit attributable to shareholders of 803 million yuan, up 12.66% year-on-year [1] - The Global Digital Trade Center is set to open in October 2025, expected to significantly boost the company's main business [2] - The company is heavily invested in the Belt and Road Initiative, with limited impact from U.S. tariffs on its operations [2] - The strategic incubation business is entering a value release phase, with Chinagoods and Yipay expected to contribute significantly to profits in 2025 [3] Financial Performance Summary - For Q1 2025, the company achieved a net profit of 803 million yuan, with a non-recurring net profit of 795 million yuan, reflecting a 15.14% increase year-on-year [1] - The company anticipates a net profit of 4.05 billion yuan in 2025, with a year-on-year growth of 31.8% [6] - The projected total revenue for 2025 is 19.682 billion yuan, representing a 25.1% increase from the previous year [8] - The gross profit margin is expected to improve from 31.4% in 2024 to 31.5% in 2025 [8] Strategic Developments - The company is enhancing its digital capabilities through AI applications, with Chinagoods achieving a revenue of 341 million yuan in 2024, a 102.05% increase year-on-year [3] - Yipay's cross-border payment system has exceeded expectations, with a total collection amount of over 4 billion USD in 2024, a 233% increase [3][5] - The company is transitioning from a consumer goods trade hub to a comprehensive trade hub covering RCEP member countries [2]